Saran Saund - Mar 31, 2021 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Role: CHIEF BUSINESS OFFICER
Signature: /s/ Saran Saund
Stock symbol: OTLC
Transactions as of: Mar 31, 2021
Transactions value $: $0
Form type: 4
Date filed: 7/16/2021, 05:35 PM
Next filing: Sep 8, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OTLC	Common Stock	Conversion of derivative security		+16.4M			16.4M	Mar 31, 2021	Direct	F1
transaction	OTLC	Common Stock	Award	$0	+103K	+0.63%	$0.00	16.5M	Jul 8, 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OTLC	Series A Convertible Preferred Stock	Conversion of derivative security		-16.4K	-100%		0	Mar 31, 2021	Common Stock	16.4M		Direct	F1, F3
transaction	OTLC	Stock Options	Award	$0	+216K		$0.00	216K	Jul 8, 2021	Common Stock	216K	$0.16	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the "Merger"), shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.
F2	Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant.
F3	Shares of the Series A Convertible Preferred Stock does not expire.
F4	Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant.